Research Radartracking 1,138 published studies · 277 human · 6 safety signals · 42 clinical trials · 44 cancer pages · updated Jul 2026Open the Research Map →
Resveratrol
Stilbenoid: SIRT1 ↑, NF-κB/apoptosis mod; moderate adjunct in breast/prostate/colorectal/lung.
Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.
👥⭐⭐⭐ Moderate — Early human studies plus extensive preclinical data; definitive oncology RCTs remain limited.RSVTrans-resveratrol3,5,4'-Trihydroxy-trans-stilbene
Forms: Micronized capsules (250-500 mg trans-resveratrol) · Liposomal or cyclodextrin-complexed for bioavailability
Educational only, not medical advice. OncoForge makes no claim that Resveratrol treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.
Key Takeaway
Pleiotropic polyphenol that activates SIRT1, suppresses NF-κB–driven inflammation, and promotes apoptosis; adjunct potential with mixed but encouraging human signals.
Evidence at a glance
Tier 2 · animalBreastProstateColorectalLung
Preclinical SIRT/NF-κB dominance; phase II PSA signals in prostate; meta-QoL modest; ongoing combos in CRC/breast; bioavailability hurdle noted.
Resveratrol (RSV) activates SIRT1→FOXO/PGC-1α deacetylation, enhancing DNA repair/mitochondrial efficiency and reducing senescence signaling. It inhibits NF-κB (IKK/p65), lowering COX-2/IL-6/TNF and angiogenic VEGF. RSV primes intrinsic apoptosis (Bax↑/Bcl-2↓, caspase-3/9) and can modulate ER/AR signaling in hormone-responsive tumors. Synergistic effects with chemo/radiation are reported preclinically and in small trials.
Targets & pathways
Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.
Sirtuin↑SIRT1 activation for DNA repair/mitochondria
Sirtuin: Overlaps pterostilbene; no additive gain.
NF-κB ↓: Redundant with curcumin; monitor inflammation.
Safety & interactions
Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.
This systematic review examined evidence linking three Mediterranean-diet components (olive oil polyphenols, red wine resveratrol, and tomato lycopene) to colorectal cancer incidence and progression. In vitro studies showed these compounds can interfere with molecular cancer pathways, and many clinical studies reported associations with reduced cancer initiation and progression. The authors conclude more clinical studies are needed to define precise doses and administration, and to evaluate these agents as adjuncts to chemoprevention or oncologic treatment.
Key findings
Olive oil polyphenols, red wine resveratrol, and tomato lycopene showed several characteristics in vitro that interfere with molecular cancer pathways.
Many clinical studies have reported an association of these components with a reduction in cancer initiation and progression.
More clinical studies are needed to identify the precise dose and administration of single agents or their combination to produce a coadjutant treatment to those already applied in chemoprevention and oncologic treatment.
Limitations: Includes in vitro data which may not translate to humans.; Clinical evidence described as associations; causality not established in the abstract.; Abstract does not report quantitative effect sizes, doses, or standardized regimens.; Authors state that more clinical studies are needed to determine precise dose and administration..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed
What changed recently
The latest additions to Resveratrol's evidence base, and anything that's been retracted.
Cancers where Resveratrol reported positive results
Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.
Limitations: Includes in vitro data which may not translate to humans.; Clinical evidence described as associations; causality not established in the abstract.; Abstract does not report quantitative effect sizes, doses, or standardized regimens.; Authors state that more clinical studies are needed to determine precise dose and administration..
A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.
No human studies yet · No numeric effect sizes reported · Based on a single study.
Dose: as studied, not a recommendation
These are doses as studied or reported, never a recommendation. The right amount of Resveratrol depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.
Ranges seen in adjunct / practice use: 250–1000 mg/day (po) divided BID; micronized for absorption, Adjunct 500 mg/day; up to 1 g for preclinical extrapolation; trans-isomer preferred; cycle if GI issues..
Trials studying Resveratrol
No actively-recruiting trials matched right now. Recruiting is not the same as proven. Search ClinicalTrials.gov →
Appears in these protocol claims
Resveratrol is named in these protocols discussed online. Listed for transparency: being part of a protocol is not evidence that it works, and OncoForge does not endorse them.
Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.